The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Te-Chun Hsia
No Relationships to Disclose
 
Jen-Yu Hung
No Relationships to Disclose
 
Hyun Ae Jung
No Relationships to Disclose
 
Jin-Yuan Shih
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Research Funding - Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Chugai Pharma; Pfizer; Roche
 
Cheol-Kyu Park
No Relationships to Disclose
 
Seung Hyeun Lee
No Relationships to Disclose
 
Tatsuro Okamoto
Honoraria - AstraZeneca; AstraZeneca (I); Johnson & Johnson; Johnson & Johnson (I); Lilly Japan; Lilly Japan (I); MSD; MSD (I); Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim (I); Taiho Pharmaceutical; Taiho Pharmaceutical (I)
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Lilly Japan (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Hee Kyung Ahn
Speakers' Bureau - AstraZeneca; Lilly; Roche
Expert Testimony - AstraZeneca; Lilly; Roche
 
Yong Chul Lee
No Relationships to Disclose
 
Yuki Sato
Honoraria - AstraZeneca; Chugai Pharma; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Sung Sook Lee
No Relationships to Disclose
 
Celine Mascaux
Honoraria - AstraZeneca; Bristol-Myers Squibb; Kephren; Merck Sharp & Dohme; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Kephren; Merck Sharp & Dohme; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
 
Hasan Daoud
Employment - Boehringer Ingelheim
 
Angela Maerten
Employment - Boehringer Ingelheim
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics; MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell; Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Merck Sharp & Dohme; Roche